Brain

Huntsville Memorial Hospital Reduces Patient Transfers and Enhances Local Care with Onsite EEG Program Powered by Zeto

HUNTSVILLE, Texas, June 11, 2025 /PRNewswire/ -- Zeto, Inc. is proud to announce the success of a new onsite EEG…

6 months ago

Precision Neuroscience Expands Leadership Team With Key Hires From Meta and FDA

Vanessa Tolosa joins as Senior Vice President of Research and Development; Vivek Pinto as Director of Medical AffairsNEW YORK, June…

6 months ago

Chiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB to Advance Blood-Brain Barrier-Crossing Therapies for Lysosomal Storage Disorders

Collaboration will leverage Key2Brain’s technology to develop blood-brain barrier-crossing enzyme replacement therapies for lysosomal storage disorders Agreement is built on…

6 months ago

Chiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB to Advance Blood-Brain Barrier-Crossing Therapies for Lysosomal Storage Disorders

Collaboration will leverage Key2Brain’s technology to develop blood-brain barrier-crossing enzyme replacement therapies for lysosomal storage disorders Agreement is built on…

6 months ago

Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases

RAD101 in U.S. Phase 2 clinical trial to distinguish between recurrent disease and treatment effect of brain metastases originating from…

6 months ago

BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD)

Improvement in depression scores, response and remission were all found to be comparable with standard Deep TMS in non-inferiority trialBURLINGTON,…

6 months ago

Pharmazz Inc. Secures $25 Million Strategic Equity Investment from Sun Pharmaceutical Industries Ltd.

Funding supports pivotal Phase 3 trial for sovateltide, a potential first-in-class therapy that could transform the treatment of acute cerebral…

6 months ago

Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era…

6 months ago